Octant emerges with $30M to untangle, exploit pathways hit by dirty drugs

With a $30 million series A round led by Andreessen Horowitz, Octant is using genetic bar codes to sort out the pathways behind the therapeutic effects of dirty GPCR modulators, and developing new agents with optimized polypharmacology for metabolic and neuropsychiatric diseases.

8VC, SV Angel, Allen & Co. and undisclosed other private investors also participated in the round...